{
    "organizations": [],
    "uuid": "6478b6d3790b222d87ac8f0278c964ea6f23d487",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aimmune-therapeutics-announces-201/brief-aimmune-therapeutics-announces-2018-outlook-including-upcoming-data-from-pivotal-phase-3-palisade-trial-of-ar101-for-peanut-allergy-idUSASB0C02P",
    "ord_in_thread": 0,
    "title": "BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Aimmune Therapeutics Inc:\n* AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY\n* AIMMUNE THERAPEUTICS INC - AR101 BLA SUBMISSION EXPECTED AT END OF 2018\n* AIMMUNE THERAPEUTICS ANNOUNCES 2018 OUTLOOK, INCLUDING UPCOMING DATA FROM PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 FOR PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS - ARTEMIS TRIAL IS ON TRACK TO COMPLETE ENROLLMENT IN Q1 OF 2018, EXPECTS DATA FROM ARTEMIS IN EARLY 2019\n* AIMMUNE THERAPEUTICS INC - ENDED 2017 WITH ABOUT $182 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017\n* AIMMUNE THERAPEUTICS INC- 2018 PLANS INCLUDE INITIATION OF ARC005 CLINICAL TRIAL OF AR101 FOR PEANUT ALLERGY IN YOUNG CHILDREN AGES 6-48 MONTHS\n* AIMMUNE THERAPEUTICS - 2018 PLANS ALSO INCLUDE INITIATION, WITH REGENERON AND SANOFI, OF PHASE 2 CLINICAL TRIAL OF AR101 AND ADJUNCTIVE DUPILUMAB\n* AIMMUNE - ALSO EXPECTS TO FILE IND APPLICATION FOR EGG ALLERGY PROGRAM IN 2018, CONTINUE WORK TOWARD FILING IND FOR WALNUT ALLERGY IN 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:15:00.000+02:00",
    "crawled": "2018-01-09T17:16:24.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "aimmune",
        "therapeutic",
        "inc",
        "aimmune",
        "therapeutic",
        "palisade",
        "completed",
        "topline",
        "result",
        "anticipated",
        "february",
        "aimmune",
        "therapeutic",
        "inc",
        "ar101",
        "bla",
        "submission",
        "expected",
        "end",
        "aimmune",
        "therapeutic",
        "announces",
        "outlook",
        "including",
        "upcoming",
        "data",
        "pivotal",
        "phase",
        "palisade",
        "trial",
        "ar101",
        "peanut",
        "allergy",
        "aimmune",
        "therapeutic",
        "artemis",
        "trial",
        "track",
        "complete",
        "enrollment",
        "q1",
        "expects",
        "data",
        "artemis",
        "early",
        "aimmune",
        "therapeutic",
        "inc",
        "ended",
        "million",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "dec",
        "aimmune",
        "therapeutic",
        "plan",
        "include",
        "initiation",
        "arc005",
        "clinical",
        "trial",
        "ar101",
        "peanut",
        "allergy",
        "young",
        "child",
        "age",
        "month",
        "aimmune",
        "therapeutic",
        "plan",
        "also",
        "include",
        "initiation",
        "regeneron",
        "sanofi",
        "phase",
        "clinical",
        "trial",
        "ar101",
        "adjunctive",
        "dupilumab",
        "aimmune",
        "also",
        "expects",
        "file",
        "ind",
        "application",
        "egg",
        "allergy",
        "program",
        "continue",
        "work",
        "toward",
        "filing",
        "ind",
        "walnut",
        "allergy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}